Versant and Lilly back new startup Seawolf Therapeutics with $100 million for viral-free gene therapy
Versant Ventures and Eli Lilly have invested $100 million into a new startup named Seawolf Therapeutics. The company aims to solve a major headache in gene therapy by delivering genes without viruses, avoiding the immune system limits and side effects tied to traditional virus-based methods.

Original image temporarily unavailable
A new biotech startup called Seawolf Therapeutics has launched with $100 million in funding from investors including Versant Ventures and Eli Lilly, alongside a partnership with Sanofi. According to the report by STAT, the company's core mission is to tackle one of the most stubborn hurdles in genetic medicine: delivering therapeutic genes without relying on viruses.
Traditional gene therapies often use viruses as delivery vehicles, which have advanced many clinical trials for rare diseases. However, these virus-based methods carry significant drawbacks, such as triggering antibodies that prevent patients from receiving more than a single dose, as well as severe side effects at high doses.
View selection rationale
Importance 68/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- STAT Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.